Edwards Lifesciences Corporation (NYSE: EW) is -8.65% lower on its value in year-to-date trading and has touched a low of $51.51 and a high of $92.08 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EW stock was last observed hovering at around $84.31 in the last trading session, with the day’s loss setting it -0.97% off its average median price target of $95.00 for the next 12 months. It is also 24.92% off the consensus price target high of $111.00 offered by 25 analysts, but current levels are -17.38% lower than the price target low of $71.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $83.34, the stock is -2.22% and -3.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.1 million and changing -1.15% at the moment leaves the stock 4.49% off its SMA200. EW registered 8.12% gain for a year compared to 6-month gain of 5.36%. The firm has a 50-day simple moving average (SMA 50) of $86.50 and a 200-day simple moving average (SMA200) of $83.20.
The stock witnessed a -4.46% loss in the last 1 month and extending the period to 3 months gives it a -2.23%, and is -4.92% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.39% over the week and 2.39% over the month.
Edwards Lifesciences Corporation (EW) has around 14900 employees, a market worth around $52.62B and $4.39B in sales. Current P/E ratio is 64.55 and Fwd P/E is 33.63. Profit margin for the company is 18.80%. Distance from 52-week low is 61.80% and -9.49% from its 52-week high. The company has generated returns on investments over the last 12 months (15.60%).
Edwards Lifesciences Corporation (EW) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Edwards Lifesciences Corporation (EW) is a “Overweight”. 25 analysts offering their recommendations for the stock have an average rating of 2.20, where 10 rate it as a Hold and 1 think it is a “Overweight”. 12 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Edwards Lifesciences Corporation is expected to release its quarterly report on 04/27/2021 and quarterly earnings per share for the current quarter are estimated at $0.48 with sales reaching $1.16B over the same period.The EPS is expected to shrink by -21.00% this year, but quarterly earnings will post 16.10% year-over-year. Quarterly sales are estimated to grow 3.20% in year-over-year returns.
Edwards Lifesciences Corporation (EW) Top Institutional Holders
1,520 institutions hold shares in Edwards Lifesciences Corporation (EW), with 4.27M shares held by insiders accounting for 0.68% while institutional investors hold 88.19% of the company’s shares. The shares outstanding are 623.50M, and float is at 620.28M with Short Float at 0.72%. Institutions hold 87.59% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 58.6 million shares valued at $5.35 billion. The investor’s holdings represent 9.38% of the EW Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 48.35 million shares valued at $4.41 billion to account for 7.74% of the shares outstanding. The other top investors are State Street Corporation which holds 25.86 million shares representing 4.14% and valued at over $2.36 billion, while Bank Of New York Mellon Corporation holds 3.49% of the shares totaling 21.78 million with a market value of $1.99 billion.
Edwards Lifesciences Corporation (EW) Insider Activity
A total of 107 insider transactions have happened at Edwards Lifesciences Corporation (EW) in the last six months, with sales accounting for 65 and purchases happening 42 times. The most recent transaction is an insider sale by Szyman Catherine M., the company’s CVP, Critical Care. SEC filings show that Szyman Catherine M. sold 3,389 shares of the company’s common stock on Feb 16 at a price of $88.20 per share for a total of $0.3 million. Following the sale, the insider now owns 26746.0 shares.
Edwards Lifesciences Corporation disclosed in a document filed with the SEC on Feb 11 that WANG HUIMIN (CVP, Japan & Intercontinental) sold a total of 11,745 shares of the company’s common stock. The trade occurred on Feb 11 and was made at $86.81 per share for $1.02 million. Following the transaction, the insider now directly holds 93213.0 shares of the EW stock.
Still, SEC filings show that on Feb 05, BOBO DONALD E JR (CVP,Strategy/Corp Development) disposed off 13,077 shares at an average price of $85.80 for $1.12 million. The insider now directly holds 48,508 shares of Edwards Lifesciences Corporation (EW).
Edwards Lifesciences Corporation (EW): Who are the competitors?
The company’s main competitors (and peers) include Boston Scientific Corporation (BSX) that is trading -8.02% down over the past 12 months. Medtronic plc (MDT) is 2.18% up on the 1-year trading charts. Short interest in the company’s stock has fallen -3.8% from the last report on Dec 30, 2020 to stand at a total of 4.64 million short shares sold with a short interest ratio of 1.71.